Ubs Group Ag Painreform Ltd. Transaction History

Ubs Group Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.43 - $0.69 $2,312 - $3,710	-5,378 Reduced 89.38%	639 $0
Q1 2023 May 12, 2023	SELL	$0.41 - $0.76 $1,732 - $3,211	-4,225 Reduced 41.25%	6,017 $4,000
Q4 2022 Feb 08, 2023	BUY	$0.36 - $0.68 $660 - $1,248	1,836 Added 21.84%	10,242 $4,000
Q3 2022 Nov 10, 2022	BUY	$0.62 - $0.96 $1,036 - $1,605	1,672 Added 24.83%	8,406 $6,000
Q2 2022 Aug 10, 2022	SELL	$0.72 - $1.31 $483 - $880	-672 Reduced 9.07%	6,734 $6,000
Q1 2022 May 16, 2022	BUY	$0.88 - $1.56 $6,517 - $11,553	7,406 New	7,406 $9,000
Q4 2021 Feb 14, 2022	SELL	$1.26 - $2.83 $2,634 - $5,917	-2,091 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.56 - $4.08 $6,599 - $10,518	-2,578 Reduced 55.22%	2,091 $6,000
Q2 2021 Aug 13, 2021	BUY	$2.33 - $4.7 $4,163 - $8,398	1,787 Added 62.01%	4,669 $13,000
Q1 2021 May 12, 2021	BUY	$4.06 - $6.82 $11,700 - $19,655	2,882 New	2,882 $13,000
Q4 2020 Feb 11, 2021	SELL	$4.16 - $5.4 $17,750 - $23,041	-4,267 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$4.6 - $6.74 $19,628 - $28,759	4,267 New	4,267 $20,000

Ticker PRFX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 10,634,200
Market Cap $129M
Description
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-oper...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.